Establishment Labs Holdings Inc. (ESTA)
| Market Cap | 1.89B |
| Revenue (ttm) | 211.08M |
| Net Income (ttm) | -51.06M |
| Shares Out | 29.39M |
| EPS (ttm) | -1.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 403,793 |
| Open | 64.75 |
| Previous Close | 65.47 |
| Day's Range | 63.50 - 66.24 |
| 52-Week Range | 28.89 - 83.31 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | 86.86 (+34.88%) |
| Earnings Date | May 6, 2026 |
About ESTA
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force. Establishment Labs Holdings Inc. was incorporated in 2004 and i... [Read more]
Financial Performance
In 2025, ESTA's revenue was $211.08 million, an increase of 27.14% compared to the previous year's $166.03 million. Losses were -$51.06 million, -39.64% less than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ESTA stock is "Strong Buy." The 12-month stock price target is $86.86, which is an increase of 34.88% from the latest price.
News
Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs® Surpasses More Than Five Million Motiva® Devices in Market
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in bre...
Establishment Labs Holdings Transcript: TD Cowen 46th Annual Health Care Conference
2025 saw exceptional U.S. growth for Motiva, driven by innovative marketing, premium pricing, and strong account expansion. 2026 guidance projects continued momentum, new product launches, and margin expansion, with international and reconstruction segments poised for further growth.
Establishment Labs Holdings Earnings Call Transcript: Q4 2025
Q4 2025 saw revenue surge 45% year-over-year, with strong US and international growth, gross margins above 70%, and a significant turnaround to positive adjusted EBITDA. 2026 guidance projects 25%+ revenue growth, continued margin expansion, and cash flow positivity.
Establishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs Announces Leadership Transition to Support Next Phase of Growth
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs to Present at TD Cowen's 46th Annual Health Care Conference
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs to Announce Fourth Quarter 2025 Financial Results on February 24
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong 2025 results with 27% global growth and rapid U.S. market share gains set the stage for at least 25% annual growth in 2026–2027. Key drivers include innovative minimally invasive products, expanded sales force, and robust marketing, with international markets and new indications poised to further accelerate growth.
Establishment Labs Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs to Present at 44th Annual J.P. Morgan Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs Holdings Transcript: Jefferies London Healthcare Conference 2025
Strong U.S. entry and innovation are driving rapid growth, with market share expected to reach 20% by year-end and minimally invasive products expanding the market. International focus on direct markets and new pipeline products like JEM and Recon Indication support long-term growth.
Establishment Labs to Present at Jefferies London Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs Holdings Earnings Call Transcript: Q3 2025
Q3 2025 delivered 34% revenue growth, record 70.1% gross margin, and the first positive EBITDA. U.S. and international direct markets showed strong momentum, with 2025 revenue guidance raised above $210M and cash flow positive targeted for 2026.
Establishment Labs Reports Third Quarter 2025 Financial Results
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs to Announce Third Quarter 2025 Financial Results on November 5
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs Notes Publication of Mia Femtech 3-Year Prospective Study Results in Aesthetic Surgery Journal
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs Publishes 15 Years of Motiva Data in 2025 Post-Market Surveillance Report
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs Holdings Earnings Call Transcript: Q2 2025
Second quarter revenue grew 16% year-over-year to $51.3 million, led by strong U.S. performance and robust European direct market growth. Adjusted EBITDA loss narrowed, and 2025 revenue guidance was raised to $208–$212 million, with positive EBITDA expected later this year.
Establishment Labs Reports Second Quarter 2025 Financial Results
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs Holdings Transcript: Investor Day 2025
Strong U.S. growth, a robust innovation pipeline, and premium pricing are driving rapid adoption and market expansion, especially with minimally invasive platforms and new indications. Surgeons and patients are fueling a shift toward safer, natural results, while the competitive landscape remains favorable.
Establishment Labs Hosting Investor Day on June 12
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and...
Establishment Labs Holdings Transcript: Jefferies Global Healthcare Conference 2025
Management highlighted a differentiated product portfolio, robust U.S. expansion, and strong financial guidance for 2025. New launches like Mia and Preservé are expanding markets and margins, while disciplined operations support EBITDA profitability by year-end.